Your browser doesn't support javascript.
loading
Fingolimod induces BAFF and expands circulating transitional B cells without activating memory B cells and plasma cells in multiple sclerosis.
Miyazaki, Yusei; Niino, Masaaki; Takahashi, Eri; Suzuki, Masako; Mizuno, Masanori; Hisahara, Shin; Fukazawa, Toshiyuki; Amino, Itaru; Nakano, Fumihito; Nakamura, Masakazu; Akimoto, Sachiko; Minami, Naoya; Fujiki, Naoto; Doi, Shizuki; Shimohama, Shun; Terayama, Yasuo; Kikuchi, Seiji.
Afiliação
  • Miyazaki Y; Department of Clinical Research, Hokkaido Medical Center, 1-1 Yamanote 5-jo 7-chome, Nishi-ku, Sapporo, Hokkaido 063-0005, Japan; Department of Neurology, Hokkaido Medical Center, 1-1 Yamanote 5-jo 7-chome, Nishi-ku, Sapporo, Hokkaido 063-0005, Japan. Electronic address: yuseimiyazaki@hok-mc.hosp.go
  • Niino M; Department of Clinical Research, Hokkaido Medical Center, 1-1 Yamanote 5-jo 7-chome, Nishi-ku, Sapporo, Hokkaido 063-0005, Japan.
  • Takahashi E; Department of Clinical Research, Hokkaido Medical Center, 1-1 Yamanote 5-jo 7-chome, Nishi-ku, Sapporo, Hokkaido 063-0005, Japan.
  • Suzuki M; Division of Neurology and Gerontology, Department of Internal Medicine, Iwate Medical University, 19-1 Uchimaru, Morioka, Iwate 020-8505, Japan.
  • Mizuno M; Division of Neurology and Gerontology, Department of Internal Medicine, Iwate Medical University, 19-1 Uchimaru, Morioka, Iwate 020-8505, Japan.
  • Hisahara S; Department of Neurology, Sapporo Medical University School of Medicine, Minami-1-jo Nishi-17-chome, Chuo-ku, Sapporo, Hokkaido 060-8556, Japan.
  • Fukazawa T; Sapporo Neurology Hospital, 2-17 Kita-21-jo Higashi-21-chome, Higashi-ku, Sapporo, Hokkaido 065-0021, Japan.
  • Amino I; Department of Neurology, Hokkaido Medical Center, 1-1 Yamanote 5-jo 7-chome, Nishi-ku, Sapporo, Hokkaido 063-0005, Japan.
  • Nakano F; Department of Neurology, Hokkaido Medical Center, 1-1 Yamanote 5-jo 7-chome, Nishi-ku, Sapporo, Hokkaido 063-0005, Japan.
  • Nakamura M; Department of Neurology, Hokkaido Medical Center, 1-1 Yamanote 5-jo 7-chome, Nishi-ku, Sapporo, Hokkaido 063-0005, Japan.
  • Akimoto S; Department of Neurology, Hokkaido Medical Center, 1-1 Yamanote 5-jo 7-chome, Nishi-ku, Sapporo, Hokkaido 063-0005, Japan.
  • Minami N; Department of Neurology, Hokkaido Medical Center, 1-1 Yamanote 5-jo 7-chome, Nishi-ku, Sapporo, Hokkaido 063-0005, Japan.
  • Fujiki N; Department of Neurology, Hokkaido Medical Center, 1-1 Yamanote 5-jo 7-chome, Nishi-ku, Sapporo, Hokkaido 063-0005, Japan.
  • Doi S; Department of Neurology, Hokkaido Medical Center, 1-1 Yamanote 5-jo 7-chome, Nishi-ku, Sapporo, Hokkaido 063-0005, Japan.
  • Shimohama S; Department of Neurology, Sapporo Medical University School of Medicine, Minami-1-jo Nishi-17-chome, Chuo-ku, Sapporo, Hokkaido 060-8556, Japan.
  • Terayama Y; Division of Neurology and Gerontology, Department of Internal Medicine, Iwate Medical University, 19-1 Uchimaru, Morioka, Iwate 020-8505, Japan.
  • Kikuchi S; Department of Neurology, Hokkaido Medical Center, 1-1 Yamanote 5-jo 7-chome, Nishi-ku, Sapporo, Hokkaido 063-0005, Japan.
Clin Immunol ; 187: 95-101, 2018 02.
Article em En | MEDLINE | ID: mdl-29079163
Patients with multiple sclerosis (MS) who are treated with fingolimod have an increased proportion of transitional B cells in the circulation, but the underlying mechanism is not known. We hypothesized that B cell-activating factor of the tumor necrosis factor family (BAFF) is involved in the process. Compared with healthy controls and untreated MS patients, fingolimod-treated MS patients had significantly higher serum concentrations of BAFF, which positively correlated with the proportions and the absolute numbers of transitional B cells in blood. Despite the elevated concentrations of BAFF in fingolimod-treated MS patients, serum levels of soluble transmembrane activator and calcium-modulating cyclophilin ligand interactor, and B cell maturation antigen were not elevated. Our results show that fingolimod induces BAFF in the circulation and expands transitional B cells, but does not activate memory B cells or plasma cells in MS, which is favorable for the treatment of this disease.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfócitos B / Fator Ativador de Células B / Cloridrato de Fingolimode / Memória Imunológica / Imunossupressores / Esclerose Múltipla Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfócitos B / Fator Ativador de Células B / Cloridrato de Fingolimode / Memória Imunológica / Imunossupressores / Esclerose Múltipla Idioma: En Ano de publicação: 2018 Tipo de documento: Article